Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S.

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

The sweeping workforce reduction that began Tuesday was made worse by mistakes and poor communication, including directions ...

Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Universities are waiting cautiously as the agency's unilateral plan to cut billions of research support dollars has already ...

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.